A Phase 3 interventional study of Enoxaparin and Apixaban in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 143 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-14.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.
Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 3rd largest by enrollment, is one of 4 that started in 2007, is one of 5 in phase 3, and was the 6th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Yale University · Sites in United States
Ages up to 17
Oregon Health and Science University · Sites in United States
Ages 15–100
By country, each count listing its studies:
Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 15
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,407 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 114 across the 42 interventional studies. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing enoxaparin in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing enoxaparin in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied
Key Inclusion Criteria
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
Drug: Apixaban · Drug: Enoxaparin-matching placebo
Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
Drug: Enoxaparin · Drug: Apixaban-matching placebo
Subcutaneous, 40 mg, once daily, 5 weeks
Also known as: Lovenox®
Oral tablets, 2.5 mg, twice daily, 5weeks
Also known as: BMS-562247, Eliquis®
Administered as injection
Administered as oral tablets
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization.
Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined.
Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated.
Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood.
Time frame: First dose of study drug (presurgery) through 30 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: \>2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): \<0.75\*preRx; platelet count (\*10\^9 cells/L): \<100,000/mm\^3; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx level; leukocytes (\*10\^3 cells/μL): \< 0.75\*LLN or \>1.25\*ULN, or if preRx LLN use \< 0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; basophils (\*10\^3 cells/μL): \>400/mm\^3; eosinophils (\*10\^3 cells/μL): \> 0.75\*10\^3 cells/μL; lymphocytes (\*10\^3 cells/μL): \>0.75\*10\^3 cells/μL; monocytes (\*10\^3 cells/μL): \>2000/mm\^3; neutrophils (\*10\^3 cells/μL): \<1.0;
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): \>3 \*ULN: alkaline phosphatase (ALP) (U/L): \>2\* ULN; aspartate aminotransferase (ASP) (U/L): \>3 \*ULN; bilirubin, direct (mg/dL): \>2\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN; calcium (mg/dL): \< 0.8\*LLN or \>1.2 \*ULN, or if preRx \<LLN use \<0.75\* preRx or \>ULN if preRx \>ULN use \> 1.25\*preRx or \<LLN; chloride (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \<LLN; bicarbonate (mEq/L): \< 0.75\* LLN or \>1.25\*ULN, or if preRx \<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; potassium (mEq/L): \< 0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \< LLN; sodium (mEq/L): \<0.95\* LLN or \>1.05×ULN, or if preRx \<LLN use \<0.95\* predose or \>ULN if preRx \>ULN use \>1.05 \*preRx or \< LLN.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): \<.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<.8\*preRx or \>ULN if preRx \>ULN use \>2\*preRx or \<LLN; protein, total (g/L): If missing preRx use ≥2, or if value ≥4 or preRx =0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; creatine kinase (U/L): \>5\*ULN; uric acid (mg/dL): \>.5\* ULN, or if preRx \>ULN use \>2\*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4.
Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug
Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period
Treatment guidelines were provided for jaundice and elevated results of liver function tests.
Time frame: First dose of study drug (presurgery) through 30 days after the last dose of study drug
Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2\*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2\*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to \<100,000/mm\^3 for patients with a baseline value \>150,000/mm\^3 or a \>50% decline, if the baseline value was ≤150,000/mm\^3.
Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Milestone | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Started | 2708 | 2699 |
| Participants who received treatment | 2673 | 2659 |
| Completed | 2484 | 2447 |
| Not completed | 224 | 252 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Adverse event | 93 | 112 |
| Withdrew: Withdrawal by subject | 86 | 99 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Poor compliance or noncompliance | 1 | 1 |
| Withdrew: No longer meets study criteria | 15 | 15 |
| Withdrew: Other | 23 | 22 |
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period | 1.39 (0.95 to 2.02) | 3.86 (3.08 to 4.83) |
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period | 0.45 (0.24 to 0.85) | 1.14 (0.77 to 1.69) |
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated.
| Percentage of events/patients evaluated | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| All-cause death | 0.11 | 0.04 |
| VTE-related death | 0.04 | 0.00 |
| PE (fatal or nonfatal) | 0.11 | 0.19 |
| Nonfatal PE | 0.07 | 0.19 |
| All DVT (n=1944, 1911) | 1.13 | 3.56 |
| Symptomatic DVT | 0.04 | 0.19 |
| Asymptomatic DVT (n=1943, 1907) | 1.08 | 3.30 |
| Proximal DVT (n=2196, 2190) | 0.32 | 0.91 |
| Distal DVT (1951, 1908) | 1.03 | 2.99 |
| Symptomatic proximal DVT | 0.04 | 0.15 |
| Asymptomatic proximal DVT (n=2195, 2187) | 0.27 | 0.73 |
| Symptomatic distal DVT | 0.04 | 0.04 |
| Asymptomatic distal DVT (n=1950, 1907) | 0.97 | 2.94 |
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary
| Percentage of events/patients evaluted | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Major bleeding | 0.82 (0.54 to 1.25) | 0.68 (0.42 to 1.08) |
| CRNM | 4.08 (3.39 to 4.90) | 4.51 (3.79 to 5.38) |
| Major or CRNM | 4.83 (4.08 to 5.71) | 5.04 (4.27 to 5.94) |
| Any bleeding | 11.71 (10.55 to 12.99) | 12.56 (11.36 to 13.88) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| SAEs | 18 | 18 |
| Bleeding AEs | 15 | 21 |
| Death | 2 | 0 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Postprocedural hematoma | 20 | 23 |
| Operative hemorrhage | 19 | 14 |
| Incision site hematoma | 14 | 10 |
| Incision site hemorrhage | 13 | 19 |
| Postprocedural hemorrhagic | 4 | 7 |
| Hematuria traumatic | 1 | 1 |
| Periorbital hematoma | 1 | 0 |
| Subcutaneous hematoma | 1 | 0 |
| Traumatic hematoma | 0 | 1 |
| Hematoma | 34 | 38 |
| Wound hemorrhage | 18 | 15 |
| Hemorrhage | 13 | 13 |
| Hematuria | 41 | 39 |
| Hemorrhage urinary tract | 1 | 1 |
| Urethral hemorrhage | 0 | 2 |
| Epistaxis | 33 | 25 |
| Hemoptysis | 3 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Bloody discharge | 16 | 13 |
| Catheter site hemorrhage | 6 | 5 |
| Injection site hemorrhage | 4 | 10 |
| Injection site hematoma | 3 | 28 |
| Infusion site hematoma | 1 | 0 |
| Vessel puncture site hematoma | 1 | 0 |
| Hematocrit decreased | 18 | 21 |
| Red blood cell count decreased | 14 | 20 |
| Blood urine present | 8 | 6 |
| Blood urine | 1 | 1 |
| Occult blood positive | 1 | 0 |
| Fibrin D dimer increased | 0 | 1 |
| Hematochezia | 6 | 2 |
| Mallory-Weiss Syndrome | 4 | 0 |
| Hematemesis | 3 | 2 |
| Melaena | 3 | 1 |
| Rectal hemorrhage | 3 | 1 |
| Gingival bleeding | 2 | 3 |
| Anal hemorrhage | 1 | 0 |
| Diarrhea hemorrhagic | 1 | 0 |
| Diverticulum intestinal hemorrhagic | 1 | 0 |
| Gastrointestinal hemorrhage | 1 | 1 |
| Intra-abdominal hematoma | 1 | 0 |
| Duodenal ulcer hemorrhage | 0 | 1 |
| Hemorrhoidal hemorrhage | 0 | 1 |
| Mouth hemorrhage | 0 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.
| Participants | Apixiban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Hemorrhagic anemia | 20 | 15 |
| Ecchymosis | 5 | 9 |
| Petechiae | 2 | 2 |
| Hemorrhage subcutaneous | 1 | 0 |
| Increased tendency to bruise | 0 | 5 |
| Vaginal hemorrhage | 2 | 0 |
| Menorrhagia | 1 | 0 |
| Uterine hemorrhage | 0 | 1 |
| Conjunctival hemorrhage | 1 | 0 |
| Hematoma infection | 1 | 0 |
| Spinal hematoma | 0 | 1 |
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Paraesthesia | 32 | 19 |
| Hypoaesthesia | 29 | 35 |
| Burning sensation | 7 | 5 |
| Peroneal nerve palsy | 5 | 6 |
| Hypotonia | 4 | 4 |
| Dysarthria | 3 | 1 |
| Paresis | 2 | 1 |
| Cervicobrachial syndrome | 1 | 1 |
| Coordination abnormal | 1 | 0 |
| Hypertonia | 1 | 1 |
| Neuropathy peripheral | 1 | 2 |
| Peripheral nerve lesion | 1 | 1 |
| Radiculitis | 1 | 0 |
| Paralysis | 0 | 1 |
| Muscular weakness | 7 | 11 |
| Nerve injury | 2 | 1 |
| Femoral nerve injury | 1 | 0 |
| Sciatic nerve injury | 1 | 0 |
| Peroneal nerve injury | 0 | 1 |
| Diplopia | 1 | 0 |
| Gait disturbance | 1 | 0 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: \>2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): \<0.75\*preRx; platelet count (\*10\^9 cells/L): \<100,000/mm\^3; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx level; leukocytes (\*10\^3 cells/μL): \< 0.75\*LLN or \>1.25\*ULN, or if preRx LLN use \< 0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; basophils (\*10\^3 cells/μL): \>400/mm\^3; eosinophils (\*10\^3 cells/μL): \> 0.75\*10\^3 cells/μL; lymphocytes (\*10\^3 cells/μL): \>0.75\*10\^3 cells/μL; monocytes (\*10\^3 cells/μL): \>2000/mm\^3; neutrophils (\*10\^3 cells/μL): \<1.0;
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Hemoglobin, low (n=2605, 2587) | 2189 | 2218 |
| Hematocrit, low (n=2554, 2536) | 1274 | 1350 |
| Platelet count, low (n=2597, 2576) | 6 | 9 |
| Erythrocytes, low (n=2558, 2540) | 1310 | 1377 |
| Leukocytes, low (n=2632, 2617) | 54 | 54 |
| Leukocytes, high (n=2632, 2617) | 385 | 360 |
| Basophils (absolute), high (n=2629, 2613) | 1 | 3 |
| Eosinophils (absolute), high (n=2629, 2613) | 75 | 70 |
| Lymphocytes (absolute), low (n=2629, 2613) | 383 | 382 |
| Lymphocytes (absolute), high (n=2629, 2613) | 3 | 3 |
| Monocytes (absolute), high (n=2629, 2613) | 9 | 11 |
| Neutrophils (absolute), low (n=2629, 2613) | 5 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): \>3 \*ULN: alkaline phosphatase (ALP) (U/L): \>2\* ULN; aspartate aminotransferase (ASP) (U/L): \>3 \*ULN; bilirubin, direct (mg/dL): \>2\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN; calcium (mg/dL): \< 0.8\*LLN or \>1.2 \*ULN, or if preRx \<LLN use \<0.75\* preRx or \>ULN if preRx \>ULN use \> 1.25\*preRx or \<LLN; chloride (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \<LLN; bicarbonate (mEq/L): \< 0.75\* LLN or \>1.25\*ULN, or if preRx \<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; potassium (mEq/L): \< 0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \< LLN; sodium (mEq/L): \<0.95\* LLN or \>1.05×ULN, or if preRx \<LLN use \<0.95\* predose or \>ULN if preRx \>ULN use \>1.05 \*preRx or \< LLN.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Alkaline phosphatase, high (n=2631, 2618) | 55 | 57 |
| Alanine aminotransferase, high (n=2629, 2616) | 50 | 83 |
| Aspartate aminotransferase, high (n=2629, 2616) | 73 | 73 |
| Bilirubin, direct, high (n=2622, 2604) | 145 | 139 |
| Bilirubin, total, high (n=2630, 2617) | 24 | 12 |
| Blood urea nitrogen (BUN), high (n=2618, 2598) | 19 | 17 |
| Creatinine, high (n=2618, 2598) | 21 | 25 |
| Calcium, total, low (n=2618, 2598) | 7 | 18 |
| Calcium, total, high (n=2618, 2598) | 0 | 1 |
| Chloride, serum, low (n=2615, 2594) | 6 | 6 |
| Bicarbonate, low (n=2615, 2595) | 8 | 8 |
| Potassium, serum, low (n=2614, 2594) | 73 | 73 |
| Potassium, serum, high (n=2614, 2594) | 61 | 47 |
| Sodium, serum, low (n=2615, 2594) | 29 | 23 |
| Sodium, serum, high (n=2615, 2594) | 5 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): \<.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<.8\*preRx or \>ULN if preRx \>ULN use \>2\*preRx or \<LLN; protein, total (g/L): If missing preRx use ≥2, or if value ≥4 or preRx =0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; creatine kinase (U/L): \>5\*ULN; uric acid (mg/dL): \>.5\* ULN, or if preRx \>ULN use \>2\*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Glucose, fasting serum, high (n=14, 17) | 0 | 1 |
| Protein, total, low (n=2618, 2596) | 747 | 752 |
| Protein, total, high (n=2618, 2596) | 3 | 1 |
| Creatine kinase, high (n=2630, 2616) | 615 | 642 |
| Uric acid, high (n=2618, 2597) | 2 | 3 |
| Blood, urine, high (n=2588, 2568) | 275 | 234 |
| Glucose, urine, high (n=2588, 2568) | 68 | 76 |
| Leukocyte esterase, urine, high (n=21, 41) | 0 | 4 |
| Protein, urine (n=2588, 2568) | 169 | 168 |
| Red blood cells (RBC), urine, high (n=1310, 1230) | 216 | 173 |
| White blood cells (WBC),urine, high (n=1311, 1228) | 217 | 229 |
Treatment guidelines were provided for jaundice and elevated results of liver function tests.
| Participants | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| Aspartate aminotransferase increased | 48 | 67 |
| Alanine aminotransferase increased | 40 | 61 |
| Gamma-glutamyltransferase increased | 27 | 54 |
| Blood bilirubin increased | 17 | 7 |
| Bilirubin conjugated increased | 11 | 12 |
| Hepatic enzyme increased | 9 | 16 |
| Liver function test results abnormal | 4 | 9 |
| Transaminases increased | 1 | 1 |
| Cholelithiasis | 2 | 0 |
| Hepatitis toxic | 2 | 0 |
| Cholecystitis acute | 1 | 0 |
| Cholestasis | 1 | 0 |
| Hyperbilirubinemia | 1 | 0 |
| Postcholecystectomy syndrome | 1 | 0 |
| Cholecystitis | 0 | 1 |
| Hepatic pain | 0 | 1 |
| Hepatitis | 0 | 1 |
| Hepatomegaly | 0 | 1 |
| Jaundice cholestatic | 0 | 1 |
| Hypoalbuminemia | 0 | 1 |
| Hypoproteinemia | 0 | 1 |
| Yellow skin | 0 | 1 |
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2\*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2\*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to \<100,000/mm\^3 for patients with a baseline value \>150,000/mm\^3 or a \>50% decline, if the baseline value was ≤150,000/mm\^3.
| Percent of events/patients evaluated | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo |
|---|---|---|
| MI/stroke | 0.22 (0.09 to 0.51) | 0.26 (0.12 to 0.56) |
| MI | 0.19 (0.07 to 0.46) | 0.11 (0.02 to 0.35) |
| Stroke | 0.04 (0.00 to 0.24) | 0.15 (0.05 to 0.41) |
| Thrombocytopenia | 0.07 (0.00 to 0.30) | 0.11 (0.02 to 0.35) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban, 2.5 mg BID + Placebo | — | 184/2,673 (6.9%) | 1,260/2,673 (47.1%) |
| Enoxaparin, 40 mg QD + Placebo | — | 172/2,659 (6.5%) | 1,315/2,659 (49.5%) |
| Event | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| Deep vein thrombosisVascular disorders | 8/2673 | 18/2659 |
| Dislocation of joint prosthesisInjury, poisoning and procedural complications | 5/2673 | 11/2659 |
| Joint dislocationInjury, poisoning and procedural complications | 8/2673 | 7/2659 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/2673 | 7/2659 |
| Device dislocationInjury, poisoning and procedural complications | 3/2673 | 7/2659 |
| Wound infectionInfections and infestations | 7/2673 | 3/2659 |
| Femur fractureInjury, poisoning and procedural complications | 6/2673 | 4/2659 |
| Atrial fibrillationCardiac disorders | 6/2673 | 3/2659 |
| HypotensionVascular disorders | 6/2673 | 4/2659 |
| OverdoseInjury, poisoning and procedural complications | 5/2673 | 5/2659 |
| Event | Apixaban, 2.5 mg BID + Placebo | Enoxaparin, 40 mg QD + Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 485/2673 | 529/2659 |
| Procedural painInjury, poisoning and procedural complications | 421/2673 | 426/2659 |
| ConstipationGastrointestinal disorders | 318/2673 | 364/2659 |
| HypotensionVascular disorders | 259/2673 | 262/2659 |
| VomitingGastrointestinal disorders | 211/2673 | 262/2659 |
| PyrexiaGeneral disorders | 236/2673 | 242/2659 |
| DizzinessNervous system disorders | 185/2673 | 154/2659 |
| Urinary retentionRenal and urinary disorders | 174/2673 | 152/2659 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 163/2673 | 156/2659 |
| Oedema peripheralGeneral disorders | 156/2673 | 141/2659 |
| Age, Continuous(Years) | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo | Total |
|---|---|---|---|
| Mean | 60.9 ± 11.79 | 60.6 ± 11.82 | 60.8 ± 11.81 |
| Age, Customized(Participants) | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo | Total |
|---|---|---|---|
| Younger than 65 years | 1608 | 1605 | 3213 |
| 65 to younger than 75 years | 770 | 767 | 1537 |
| 75 years and older | 330 | 327 | 657 |
| Sex: Female, Male(Participants) | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo | Total |
|---|---|---|---|
| Female | 1430 | 1451 | 2881 |
| Male | 1278 | 1248 | 2526 |
| Region of Enrollment(Participants) | Apixaban, 2.5 mg BID Plus Placebo | Enoxaparin, 40 mg QD Plus Placebo | Total |
|---|---|---|---|
| United States | 450 | 441 | 891 |
| Spain | 32 | 29 | 61 |
| Ukraine | 217 | 219 | 436 |
| Russian Federation | 274 | 276 | 550 |
| Israel | 57 | 56 | 113 |
| United Kingdom | 77 | 78 | 155 |
| India | 56 | 56 | 112 |
| France | 75 | 74 | 149 |
| Hungary | 152 | 150 | 302 |
| Mexico | 73 | 74 | 147 |
| Canada | 359 | 356 | 715 |
| Argentina | 53 | 54 | 107 |
| Belgium | 59 | 60 | 119 |
| Poland | 184 | 185 | 369 |
| Romania | 24 | 25 | 49 |
| Australia | 101 | 99 | 200 |
| Denmark | 99 | 99 | 198 |
| Germany | 135 | 134 | 269 |
| Norway | 47 | 48 | 95 |
| China | 121 | 124 | 245 |
| Sweden | 63 | 62 | 125 |
Showing the first 100 of 143 sites across 21 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 4 years 8 months after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin